Posted by Michael Wonder on 10 Feb 2022
Theragnostics announces that its radiotherapeutic for treatment of glioblastoma multiforme has been awarded UK's MHRA innovation passport
10 February 2022 - Promising non-clinical results support Phase 1 clinical study in recurrent glioblastoma multiforme.
Theragnostics today announces that its novel I-123 PARPi (THG-009) therapeutic agent has been awarded an Innovation Passport by the UK Medicines and Healthcare products Regulatory Agency for the treatment of primary and recurrent Glioblastoma Multiforme.
